Many drugs can be used for adjuvant therapy of breast cancer, including anthracyclines, cyclophosphamide, 5-fluorouracil (5-fU) and, recently, taxanes (TXT) have shown promising results. 5-FU blocks thymidylate synthase (TS) which cross-links p53 mRNA, inhibiting its synthesis. TS overexpression is one of the main mechanisms involved in 5-FU drug resistance. Enough p53 mutations can confer resistance to chemotherapy using anthracyclines and 5-FU, while are associated with improved responses to TXT. The aim of this study was to examine the TS and p53 levels in tumor samples and to compare the efficacy of FEC (5-FU, epirubicin, cyclophosphamide) and TXT chemotherapy in a group of patients with differing TS and p53 status. We examined 84 breast tumor samples using immunohistochemistry. TS and p53 levels were inversely related, and TS and p53 positivity was significantly associated with the failure of FEC treatment and with a good response to TXT therapy (p <0.001). This confirms the predictive role of these two markers, which should be considered when choosing the appropriate adjuvant therapy for breast cancer.

Calascibetta, A., Martorana, A., Cabibi, D., Aragona, F., Sanguedolce, R. (2011). Relationship between Thymidylate synthase and p53 and response versus taxane adjuvant chemotherapy for breast carcinoma. JOURNAL OF CHEMOTHERAPY, 23(Vol 23 issue 6), 354-357.

Relationship between Thymidylate synthase and p53 and response versus taxane adjuvant chemotherapy for breast carcinoma

CALASCIBETTA, Anna;MARTORANA, Anna;CABIBI, Daniela;ARAGONA, Federico;SANGUEDOLCE, Rosario
2011-01-01

Abstract

Many drugs can be used for adjuvant therapy of breast cancer, including anthracyclines, cyclophosphamide, 5-fluorouracil (5-fU) and, recently, taxanes (TXT) have shown promising results. 5-FU blocks thymidylate synthase (TS) which cross-links p53 mRNA, inhibiting its synthesis. TS overexpression is one of the main mechanisms involved in 5-FU drug resistance. Enough p53 mutations can confer resistance to chemotherapy using anthracyclines and 5-FU, while are associated with improved responses to TXT. The aim of this study was to examine the TS and p53 levels in tumor samples and to compare the efficacy of FEC (5-FU, epirubicin, cyclophosphamide) and TXT chemotherapy in a group of patients with differing TS and p53 status. We examined 84 breast tumor samples using immunohistochemistry. TS and p53 levels were inversely related, and TS and p53 positivity was significantly associated with the failure of FEC treatment and with a good response to TXT therapy (p <0.001). This confirms the predictive role of these two markers, which should be considered when choosing the appropriate adjuvant therapy for breast cancer.
Settore BIO/14 - Farmacologia
Settore MED/08 - Anatomia Patologica
Calascibetta, A., Martorana, A., Cabibi, D., Aragona, F., Sanguedolce, R. (2011). Relationship between Thymidylate synthase and p53 and response versus taxane adjuvant chemotherapy for breast carcinoma. JOURNAL OF CHEMOTHERAPY, 23(Vol 23 issue 6), 354-357.
File in questo prodotto:
File Dimensione Formato  
Calascibetta.pdf

Solo gestori archvio

Descrizione: Articolo principale
Dimensione 354.01 kB
Formato Adobe PDF
354.01 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/64912
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 4
social impact